drugset / Trial / NCT00753064

AScVS and/ or Prazosin for Scorpion Envenomation

NCT00753064

Phase 3 Completed 81 enrolled Haffkine Bio-Pharmaceutical Corporation Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The data available for the efficacy of AScVS and prazosin is generated through different trials done in different clinical setting. Hence it was felt worthwhile to confirm the documented efficacy of AScVS and prazosin in terms of time taken for clinical recovery in a clinical trial. Along with this, effects of both the therapies on various biochemical parameters will be recorded and compared with. It was also felt necessary to study the effect of combination on the clinical outcome.

Timeline

Start
2006-09
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Antiscorpion venom serum Protein / enzyme biologic 1 unknown Intravenous
Comparator Antiscorpion venom serum Protein / enzyme biologic 2 unknown Intravenous
Comparator Antiscorpion venom serum Protein / enzyme biologic 3 unknown Intravenous
Comparator Antiscorpion venom serum Protein / enzyme biologic 4 unknown Intravenous
Comparator Antiscorpion venom serum Protein / enzyme biologic 6 unknown Intravenous
Comparator Antiscorpion venom serum Protein / enzyme biologic 8 unknown Intravenous
Comparator Prazosin Unknown 30 ug/kg Oral
Comparator Prazosin Unknown 500 ug Oral
Comparator Prazosin Unknown 1 mg Oral

Indications